Success Metrics

Clinical Success Rate
100.0%

Based on 9 completed trials

Completion Rate
100%(9/9)
Active Trials
0(0%)
Results Posted
22%(2 trials)

Phase Distribution

Ph phase_2
1
10%
Ph phase_1
4
40%
Ph phase_4
3
30%
Ph not_applicable
1
10%
Ph phase_3
1
10%

Phase Distribution

4

Early Stage

1

Mid Stage

4

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
4(40.0%)
Phase 2Efficacy & side effects
1(10.0%)
Phase 3Large-scale testing
1(10.0%)
Phase 4Post-market surveillance
3(30.0%)
N/ANon-phased studies
1(10.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

9 of 9 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

10

all time

Status Distribution
Completed(9)
Other(1)

Detailed Status

Completed9
unknown1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 14 (40.0%)
Phase 21 (10.0%)
Phase 31 (10.0%)
Phase 43 (30.0%)
N/A1 (10.0%)

Trials by Status

unknown110%
completed990%

Recent Activity

0 active trials
Showing 5 of 10
completedphase_1

Assessment of Interaction Between Vytorin and Niaspan in Healthy Subjects (P04955AM2)

NCT00652431
completedphase_4

Effectiveness of Intensive Lipid Modification Medication in Preventing the Progression of Peripheral Arterial Disease (The ELIMIT Study)

NCT00687076
completedphase_2

Study to Test GSK256073 in Patients With Dyslipidemia

NCT00903617
completedphase_4

Benefit of Elevation of HDL-C in Women

NCT01921010
completedphase_1

Effects of Niaspan™ on High-density Lipoprotein (HDL) in Healthy Male Subjects (0000-069)

NCT01071291
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT00652431Phase 1

Assessment of Interaction Between Vytorin and Niaspan in Healthy Subjects (P04955AM2)

Completed
NCT00687076Phase 4

Effectiveness of Intensive Lipid Modification Medication in Preventing the Progression of Peripheral Arterial Disease (The ELIMIT Study)

Completed
NCT00903617Phase 2

Study to Test GSK256073 in Patients With Dyslipidemia

Completed
NCT01921010Phase 4

Benefit of Elevation of HDL-C in Women

Completed
NCT01071291Phase 1

Effects of Niaspan™ on High-density Lipoprotein (HDL) in Healthy Male Subjects (0000-069)

Completed
NCT01720095Phase 3

Niapsan as Add -on Therapy to Antipsychotic Treatment in First Episode Psychosis

Completed
NCT01104519Phase 1

A Study of Niaspan on Endothelium-Dependent and Endothelium-Independent Vascular Reactivity (0000-093)

Completed
NCT01809301Phase 1

Comparison of TRIA-662 500 mg and Niaspan 1000 mg in Healthy Male and Female Volunteers Under Fed Conditions

Completed
NCT00590629Phase 4

Benefit of Elevation of HDL-C on Cardiovascular Outcomes in Women

Completed
NCT00232531Not Applicable

Oxford Niaspan Study: Effects of Niaspan on Atherosclerosis and Endothelial Function

Unknown

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10